GlassScriptPhysician profile
Charles Edward Holt
NPI 1689772519
$2,755.03
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $437 · 2021: $48.52 · 2022: $499 · 2023: $632 · 2024: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.02 | 2021-2024 | |
| Novo Nordisk INC | $301.73 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $237.08 | 2019-2024 | Mounjaro, Trulicity, Zepbound |
| Astrazeneca Pharmaceuticals LP | $212.04 | 2019-2024 | Farxiga |
| Pfizer INC. | $191.59 | 2019-2024 | |
| Mylan Specialty L.P. | $173.29 | 2020-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $154.08 | 2019-2021 | |
| Axsome Therapeutics, INC. | $126.31 | 2023-2024 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.35 | 2019-2024 | Jardiance |
| Astellas Pharma US INC | $94.67 | 2019-2024 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.62 | 2019-2024 | Trulance, Xifaxan |
| Bausch Health US, LLC | $67.83 | 2022-2024 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $65.62 | 2019-2022 | |
| Abbott Laboratories | $55.99 | 2022-2023 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $47.14 | 2019-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $46.70 | 2019-2024 | Repatha, Otezla |
| Antares Pharma, INC. | $40.98 | 2020-2022 | |
| Amarin Pharma, INC. | $36.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $35.54 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $35.10 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.75 | 2020-2023 | |
| Medtronic, INC. | $32.62 | 2022-2024 | Intellis Adaptivestim |
| Sanofi-Aventis U.S. LLC | $29.81 | 2019 | |
| Circassia INC. | $27.18 | 2019 | |
| Allergan, INC. | $24.65 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.75 | 2019 | |
| Lundbeck LLC | $20.78 | 2024 | Rexulti |
| Boston Scientific Corporation | $18.13 | 2023 | Wavewriter Alpha Prime 16 |
| Upsher-Smith Laboratories LLC | $17.06 | 2020 | |
| Jazz Pharmaceuticals INC. | $15.98 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.96 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $13.74 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $13.55 | 2020 | |
| Exact Sciences Corporation | $13.20 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $12.44 | 2022 | |
| Arbor Pharmaceuticals, INC. | $12.06 | 2020 | |
| Genentech USA, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.